生命科学资讯

Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq

Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology - PR Newswire

GRAIL Inc. - Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha

Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside - Insider Monkey

Illumina: What Is Next In This Sequence? (NASDAQ:ILMN) - Seeking Alpha

The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance - Yahoo Finance Singapore

Cathie Wood's weekly update: buys Broadcom, AMD; sells Tesla, Illumina - MSN

Oncology Research Solutions - Illumina

Fierce Pharma Asia—AbbVie’s bispecific play, Illumina’s China import efforts and pharma execs’ JPM comments - Fierce Pharma

Genetic Disease Research Solutions - Illumina

2026: A turning point for precision health - Illumina

JPM26: Illumina working with China on 'a path through' its export troubles, sees academic research environment 'muted' for '26

JPM: Illumina working with China on export troubles, CEO says - Fierce Biotech

Illumina unveils massive cell atlas to speed up drug discovery - San Diego Union-Tribune

Illumina CEO Sees Big Growth Opportunity in China - Bloomberg.com

JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology